Surgery remains the preferred treatment option for early-stage gallbladder cancer (GBC). According to the anatomical position of the primary tumor, accurate preoperative stage and strict control of surgical indications, appropriate surgical strategies are selected to achieve the optimal surgical effect. However, most patients have already been at the locally advanced stage or the tumor has metastasized at the initial diagnosis. The postoperative recurrence rate and 5-year survival rate remain unsatisfactory even after radical resection for gallbladder cancer. Hence, there is an urgent need for more treatment options, such as neoadjuvant therapy, postoperative adjuvant therapy and first-line and second-line treatments of local progression and metastasis, in the whole-course treatment management of gallbladder cancer patients. In recent years, the application of molecular targeted drugs and immunotherapy has brought greater hope and broader prospects for the treatment of gallbladder cancer, but their effects in improving the prognosis of patients still lack sufficient evidence-based medicine evidence, so many problems should be addressed by further research. Based on the latest progress in gallbladder cancer research, this review systematically analyzes the treatment trends of gallbladder cancer.
Riboflavin kinase (RFK) is essential in riboflavin metabolism, converting riboflavin to flavin mononucleotide (FMN), which is further processed to flavin adenine dinucleotide (FAD). While RFK enhances macrophage phagocytosis of Listeria monocytogenes, its role in macrophage polarization is not well understood. Our study reveals that RFK deficiency impairs M(IFN-γ) and promotes M(IL-4) polarization, both in vitro and in vivo. Mechanistically, RFK interacts with inducible nitric oxide (NO) synthase (iNOS), which requires FMN and FAD as cofactors for activation, leading to increased NO production that alters energy metabolism by inhibiting the tricarboxylic acid cycle and mitochondrial electron transport chain. Exogenous FAD reverses the metabolic and polarization changes caused by RFK deficiency. Furthermore, bone marrow adoptive transfer from high-riboflavin-fed mice into wild-type tumor-bearing mice reprograms tumor-associated macrophage polarization and inhibits tumor growth. These results suggest that targeting RFK-iNOS or modulating riboflavin metabolism could be potential therapies for macrophage-related immune diseases.
Dysregulation of macrophage-mediated inflammatory responses is central to sepsis pathogenesis, making its modulation crucial for reducing organ damage and mortality. This study reveals that the key serine synthesis enzyme phosphoglycerate dehydrogenase (PHGDH), known for regulating tumor and immune cell functions, is significantly downregulated in mouse macrophages following lipopolysaccharide (LPS) stimulation, as well as in patients with systemic inflammatory response syndrome or sepsis. PHGDH knockdown enhances inflammatory responses to LPS and Escherichia coli in vitro, while myeloid PHGDH knockout exacerbates inflammation and organ damage in septic mouse models. In contrast, deficiency in serine and its derivative glycine inhibits LPS-induced macrophage inflammation both in vitro and in vivo. Mechanistically, PHGDH interacts with transforming growth factor-β-activated kinase 1 (TAK1), inhibiting TAK1 binding to TAK1-binding protein, thereby suppressing the TAK1-NF-κB/MAPK signaling pathway. Furthermore, adeno-associated virus-mediated PHGDH overexpression in lung macrophages reduces sepsis-related inflammation and damage, highlighting PHGDH's nonmetabolic role in regulating macrophage-mediated inflammation and suggesting new therapeutic strategies for sepsis treatment.